OBJECTIVE： To observe the therapeutic efficacy and safety of modified Liujunzi decoction in adjuvant chemotherapy for advanced non-small cell lung cancer （NSCLC）. METHODS： A total of 118 patients with advanced NSCLC were randomly divided into observation group and control group， with 59 cases in each group. Both groups were given Dexamethasone acetate tablets 15 mg orally 12， 6 h before chemotherapy， Diphenhydramine hydrochloride injection 20 mg intramuscularly 30 min before chemotherapy， and also given routine treatment as acid suppression， liver protection， antiemetic， hydration and dieresis. Control group was additionally given Paclitaxel injection 175 mg/m2 intravenously within 3 h， d1， and 30 min later given Cisplatin for injection 25 mg/m2 intreavenously for 2 h， d1-3. Observation group was additionally given modified Liujunzi decoction， decocted to 200 mL， one dose a day， morning and night， on the basis of control group. A treatment course of 2 groups lasted for 21 d， and both received 4 courses. The short-term efficacies of 2 groups were observed. The levels of T lymphocyte subset and tumor marker （CEA， SCC-Ag， CYFRS21-1）， the occurrence of toxic reaction were observed before and after chemotherapy. RESULTS： Total response rate of observation group （49.15％） was significantly higher than that of control group（32.20％）； the incidence of thrombocytopenia， leucopenia， abnormal liver function， digestive tract reaction and peripheral nerve injury was significantly lower than control group， with statistical significance （P＜0.05）. After treatment， CD4+ and CD4+/CD8+ of observation group were significantly higher than before chemotherapy， while CD8+ was significantly lower than before chemotherapy； CD4+ and CD4+/CD8+ of control group were significantly lower than before chemotherapy， while CD8+ was significantly higher than before chemotherapy； CD4+ and CD4+/CD8+ of observation group were significantly higher than those control group， while CD8+ was significantly lower than control group； The levels of tumor markers in 2 groups were significantly lower than before chemotherapy， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. CONCLUSIONS： Based on routine treatment， modified Liujunzi decoction shows significant therapeutic efficacy for NSCLC， improves immune function and relieve toxic reaction.